Delivery Order SPE2DB20D9331-SPE2DB25FL2A8
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $3,868.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the provision of Xolair 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 17, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order for XOLAIR 150 MG/ML syringes valued at $3,094.80. The contract, which was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, carries firm fixed-price terms and does not utilize a set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 10, 2025, is scheduled for ultimate completion by October 1, 2025, with performance taking place at the awardee's Park Ridge facility. The contract was awarded without a set-aside designation,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $77,370 by the Defense Logistics Agency's Medical Supply Chain on September 9, 2025. The contract covers the supply of XOLAIR 150 mg/ml syringes, a biologic medication used to treat moderate to severe allergic asthma and chronic idiopathic urticaria. This firm fixed-price delivery order, with an ultimate completion date of September 30, 2025,...
- The Defense Logistics Agency awarded a delivery order valued at $1,547.40 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml syringes on August 25, 2025, with an ultimate completion date of September 16, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a single pharmaceutical product delivery to support Department of Defense healthcare operations. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based...
- The Defense Logistics Agency awarded a delivery order valued at $13,926.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 12, 2025, with an ultimate completion date of October 3, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract carries no...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,094.80 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its Park Ridge location with an ultimate completion date of October 2, 2025. This delivery order was issued without a set-aside designation, leveraging the company's competitive capabilities...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The contract, valued at $27,907.20 with a firm fixed-price structure, is scheduled for completion by September 5, 2025, and was awarded on August 14, 2025. This delivery order carries no set-aside designation and leverages DMS Pharmaceutical Group's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, valued at $1,547.40 with an ultimate completion date of September 10, 2025, was issued without set-aside designation. DMS Pharmaceutical Group competes effectively in federal procurement leveraging its small business status and established...
- The Defense Logistics Agency awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, issued on September 9, 2025, carries an ultimate completion date of September 30, 2025, with no set-aside designation applied. The contract represents a discrete fulfillment under DMS Pharmaceutical Group's...
- SPE2DB20D9331Indefinite Delivery Contract
- SPE2DB20D9331-SPE2DB25FL2A8Delivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $15,474.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 MG/ML syringes. The award, issued on September 16, 2025, with an ultimate completion date of October 7, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA valued at $499.999 billion and valid through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products to support Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through its long-standing relationship with the Defense Logistics Agency, leveraging its woman-owned small business status to compete effectively in federal procurement markets. The company's contract portfolio demonstrates extensive experience delivering specialized pharmaceutical products, including biologics, branded and generic prescription drugs, and medical consumables to military health facilities. XOLAIR, a biologic medication used for treating moderate to severe allergic asthma and chronic spontaneous urticaria, represents the type of specialized pharmaceutical product the vendor routinely supplies to support the medical readiness and healthcare needs of the Department of Defense.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.5k | 9/16/25 |